

# Human–mouse cystic fibrosis transmembrane conductance regulator (CFTR) chimeras identify regions that partially rescue CFTR- $\Delta$ F508 processing and alter its gating defect

Qian Dong<sup>a,1</sup>, Lynda S. Ostedgaard<sup>a,1</sup>, Christopher Rogers<sup>a,2</sup>, Daniel W. Vermeer<sup>a,3</sup>, Yiping Zhang<sup>a</sup>, and Michael J. Welsh<sup>a,b,c,4</sup>

Departments of <sup>a</sup>Internal Medicine and <sup>b</sup>Molecular Physiology and Biophysics and <sup>c</sup>Howard Hughes Medical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242

Contributed by Michael J. Welsh, December 6, 2011 (sent for review April 22, 2011)

The  $\Delta$ F508 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene is the most common cause of cystic fibrosis. The mutation disrupts biosynthetic processing, reduces channel opening rate, and decreases protein lifetime. In contrast to human CFTR (hCFTR)- $\Delta$ F508, mouse CFTR- $\Delta$ F508 is partially processed to the cell surface, although it exhibits a functional defect similar to hCFTR- $\Delta$ F508. To explore  $\Delta$ F508 abnormalities, we generated human–mouse chimeric channels. Substituting mouse nucleotide-binding domain-1 (mNBD1) into hCFTR partially rescued the  $\Delta$ F508-induced maturation defect, and substituting mouse membrane-spanning domain-2 or its intracellular loops (ICLs) into hCFTR prevented further  $\Delta$ F508-induced gating defects. The protective effect of the mouse ICLs was reverted by inserting mouse NBDs. Our results indicate that the  $\Delta$ F508 mutation affects maturation and gating via distinct regions of the protein; maturation of CFTR- $\Delta$ F508 depends on NBD1, and the  $\Delta$ F508-induced gating defect depends on the interaction between the membrane-spanning domain-2 ICLs and the NBDs. These appear to be distinct processes, because none of the chimeras repaired both defects. This distinction was exemplified by the I539T mutation, which improved CFTR- $\Delta$ F508 processing but worsened the gating defect. Our results, together with previous studies, suggest that many different NBD1 modifications improve CFTR- $\Delta$ F508 maturation and that the effect of modifications can be additive. Thus, it might be possible to enhance processing by targeting several different regions of the domain or by targeting a network of CFTR-associated proteins. Because no one modification corrected both maturation and gating, perhaps more than a single agent will be required to correct all CFTR- $\Delta$ F508 defects.

anion channel | protein biosynthesis

Mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel cause cystic fibrosis (CF) (1, 2). The most common CF mutation deletes Phe508 ( $\Delta$ F508, also called *F508del*). CFTR- $\Delta$ F508 is misprocessed; it fails to escape the endoplasmic reticulum (ER) and is degraded rather than trafficking to the cell membrane (3–6). Reducing the incubation temperature allows CFTR- $\Delta$ F508 channels to escape ER retention; however, compared with wild-type (WT) CFTR, they have a reduced open state probability ( $P_o$ ) and a shorter lifetime at the cell membrane (7–10). Crystal structures locate F508 on the solvent-exposed surface of nucleotide-binding domain (NBD)-1 and away from the NBD1/NBD2 dimer interface (11–13). Based on crystal structures of bacterial ATP-binding cassette (ABC) transporters and cross-linking studies, this exposed position may contact the intracellular loops (ICLs) of the membrane-spanning domains (MSDs) (14–16).

A recent cross-species comparison showed that mouse CFTR (mCFTR)- $\Delta$ F508 is partially processed like its wild-type counterpart (17). Partial processing occurred in cell types from several species, suggesting that it was not likely attributable to the presence or absence of a specific chaperone or other cellular protein.

Given the similarities between mCFTR and human CFTR (hCFTR), these data also suggested that small sequence differences might significantly influence CFTR- $\Delta$ F508 biosynthesis. Differences between hCFTR- $\Delta$ F508 and mCFTR- $\Delta$ F508 provided an opportunity to learn more about the structural determinants of CFTR- $\Delta$ F508 processing, as well as its gating. Therefore, we hypothesized that substituting sequences of mCFTR into hCFTR might prevent the  $\Delta$ F508 defects. To test this hypothesis, we generated human–mouse CFTR (hmCFTR) chimeras with and without the  $\Delta$ F508 mutation and examined the effects on biosynthetic processing and gating.

## Results

**Inserting mNBD1 into hCFTR Partially Rescues the  $\Delta$ F508 Processing Defect.** We constructed chimeras with an hCFTR backbone (Fig. 1 *A* and *B*) and assessed processing by examining CFTR glycosylation. CFTR undergoes core glycosylation in the ER and migrates as “band B” on electrophoresis; after reaching the Golgi complex, it is more extensively glycosylated and migrates as “band C” (3–5).

Wild-type hCFTR, mCFTR, and all the NBD and MSD chimeras generated band C (Fig. 1 *C* and *D*). Consistent with previous reports, the  $\Delta$ F508 mutation prevented processing of hCFTR, whereas mCFTR- $\Delta$ F508 generated substantial band C (17). Interestingly, when we introduced mNBD1- $\Delta$ F508 into hCFTR (hmNBD1- $\Delta$ F508), the chimera generated band C at levels similar to those of mCFTR- $\Delta$ F508 (Fig. 1 *C* and *D*), indicating partial rescue of the processing defect. In contrast, mNBD2, mMSD1, and mMSD2 substitutions did not rescue the misprocessing. These results suggest that the “permissive” properties that allow mCFTR- $\Delta$ F508 processing are largely confined to mNBD1. In addition, pulse-chase experiments showed that the degradation rate of hmNBD1- $\Delta$ F508 did not substantially differ from that of hmNBD1 (Fig. S1).

**mNBD1 Regulatory Extension Improves hCFTR- $\Delta$ F508 Processing.** To identify portions of mNBD1 responsible for improved hmNBD1- $\Delta$ F508 processing, we replaced smaller regions of hNBD1, choosing regions based on hNBD1 and mNBD1 crystal structures (11, 12) and differences between human and mouse primary se-

Author contributions: Q.D., L.S.O., and M.J.W. designed research; Q.D., L.S.O., C.R., D.W.V., and Y.Z. performed research; Q.D., L.S.O., and M.J.W. analyzed data; and Q.D., L.S.O., and M.J.W. wrote the paper.

The authors declare no conflict of interest.

Freely available online through the PNAS open access option.


<sup>1</sup>Q.D. and L.S.O. contributed equally to this work.

<sup>2</sup>Present address: Exemplar Genetics, Coralville, IA 52241.

<sup>3</sup>Present address: Sanford Research, Sioux Falls, SD 57104.

<sup>4</sup>To whom correspondence should be addressed. E-mail: michael-welsh@uiowa.edu.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1120065109/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1120065109/-DCSupplemental).



**Fig. 1.** Processing of hmCFTR chimeras. (A) Boundaries of the NBD and MSD chimeras. (B) Amino acid comparison of hNBD1 and mNBD1. Mouse residues that differ from human residues are highlighted in yellow. Walker A, Walker B, and signature motifs (SMs) are shaded in gray. F508 and I539 are shown in blue boxes. RI (RI<sub>1</sub>, 389–432 and RI<sub>2</sub>, 404–436) and RE (633–671) boundaries refer to the regions identified in the NBD1 crystal structure (11) and are denoted in red boxes. (C) Autoradiographs of immunoprecipitated and in vitro-phosphorylated human, mouse, and human-mouse chimeras. Bands B and C are indicated by arrows. (D) Quantitation of band C relative to the total of bands B and C. Statistical significance was tested with one-way ANOVA with a Dunnett multiple comparison posttest. \*Difference compared with hCFTR-ΔF508 ( $P < 0.05$ ). <sup>†</sup>Difference in hmRE/I539T compared with hmRE and I539T ( $P < 0.05$ ) (hCFTR,  $n = 15$ ; mCFTR,  $n = 13$ ; hmNBD1,  $n = 11$ ; hmNBD2,  $n = 6$ ; hmMSD1,  $n = 3$ ; hmMSD2,  $n = 7$ ; hmRI<sub>1</sub>,  $n = 3$ ; hmRI<sub>2</sub>,  $n = 2$ ; hmRE,  $n = 7$ ; hmRI<sub>1</sub>/RE,  $n = 5$ ; human-mouse Center,  $n = 6$ ; hI539T,  $n = 4$ ; hmRE/I539T,  $n = 4$ ).

quences (Fig. 1A and B). CFTR NBD1 contains two regions not present in other ABC transporters: an N-terminal sequence called the regulatory insertion (RI) and a C-terminal sequence called the regulatory extension (RE) (11).

Substituting portions of mNBD1 did not alter the glycosylation pattern of WT hCFTR (Fig. 1C and D). However, mouse RE (mRE) alone and together with mouse RI<sub>1</sub> (mRI<sub>1</sub>) increased hCFTR-ΔF508 band C production toward that of mCFTR-ΔF508. In contrast, mRI<sub>1</sub>, mRI<sub>2</sub>, and mouse Center failed to improve CFTR-ΔF508 processing (Fig. 1C and D). We also individually mutated eight residues that differ between mRE and human RE (hRE), but no one mutation improved hCFTR-ΔF508 processing (Fig. S2). Thus, partial rescue depended on more than one difference between the mRE and hRE.

hNBD1 has an Ile at residue 539, whereas mNBD1 has a Thr (Fig. 1B). Previous reports indicated that an I539T mutation partially improved hCFTR-ΔF508 processing (18–20). We found the same (Fig. 1C and D). In addition, we found that combining


I539T with human-mouse RE (hmRE) caused hCFTR-ΔF508 to produce more band C than either substitution alone. Moreover, the proportion of band C in the chimera containing hmRE plus I539T was similar to that obtained when the entire mNBD1-ΔF508 replaced the human domain. Interestingly, mouse Center (433–632) contains T539 but did not rescue CFTR-ΔF508 processing, suggesting that the surrounding context is also important for rescue (Fig. 1C and D).

Thus, the mNBD1 sequence is sufficient to correct hCFTR-ΔF508 processing partially, and more than one region of NBD1 is involved.

**mMSD2 Prevents ΔF508 from Increasing Interburst Interval.** We asked whether the chimeras would prevent the ΔF508 gating defect, a prolonged interburst interval (8, 21). None of the mNBD1 or mMSD1 chimeras significantly altered the interburst interval of wild-type CFTR, whereas hmNBD2 and hmMSD2 prolonged it (Figs. 2A and 3). Of all the chimeras, only hmMSD2 prevented







**Fig. 4.** Single-channel kinetic properties of CFTR MSD2 chimeras. (A) Amino acid alignment of human and mouse ICL3 and ICL4. Residues that differ from human residues are highlighted in yellow. The red boxes denote the mutations that we studied. (B–D) Single-channel kinetic properties of indicated variants. Data are the mean  $\pm$  SEM ( $n = 3$ –13 membrane patches for each construct). Details are provided in the legend for Fig. 2. \* $\Delta F508$  variant differed from its WT counterpart ( $P < 0.05$ ). #Difference of non- $\Delta F508$  variant compared with WT hCFTR ( $P < 0.05$ ).

soned that replacing the human NBDs with mouse NBDs would eliminate the protective effect. Indeed, an mNBD2 eliminated the protective effect of the ICL3 mutation (LNT<sub>964-966</sub>ISK), and an mNBD1 eliminated the protective effect of the ICL4 mutant P1072T (Fig. 4B). These effects were specific because mNBD2 did not revert the effect of the ICL4 mutant and mNBD1 did not revert the effect of the ICL3 mutant. These data further suggest that interactions between the NBDs and the MSD2 ICLs influence the effect of the  $\Delta F508$  mutation on gating.

## Discussion

### mNBD1 Sequences Partially Rescue $\Delta F508$ -Induced Processing Defects.

We found that mNBD1 was permissive for CFTR- $\Delta F508$  processing, and much of the effect was recapitulated by the RE segment. However, mutating I539T to the mouse sequence also partially rescued processing, and the mouse RE and I539T were additive in their effects. The RE is predicted to lie on the solvent-exposed surface of the NBD1, away from F508, whereas I539 lies close to the predicted NBD1 homodimer interface and faces the ICLs (12).

Other variants can also improve CFTR- $\Delta F508$  biosynthesis. (i) A genetic approach identified second-site suppressor mutations, including I539T, G550E, R553M/Q, and R555K (18–21, 25, 26). None of these lie in the RE. (ii) Other studies examined NBD1 mutations that improve its solubility for crystallization, including residues in the RE, in the RI, between the RI and RE, and around the LSGGQ motif (12). Double or triple combinations of some solubilizing mutations improved CFTR- $\Delta F508$  processing (27). (iii) Mutating residues comprising an ER retention

motif enhanced hCFTR- $\Delta F508$  biosynthesis (26, 28–30). (iv) Deleting the NBD1 RI also restored hCFTR- $\Delta F508$  maturation (31).

Our data, together with these other studies, point to the sequence and structure of NBD1 as critical for hCFTR- $\Delta F508$  processing. Substitutions, single amino acid mutations, and deletions scattered throughout the domain and largely located on its surface improved CFTR- $\Delta F508$  maturation. In addition, earlier studies indicated that the  $\Delta F508$  mutation altered NBD1 structure little other than locally modifying the surface in the region of F508 (12). These observations may allow speculation about the mechanisms by which NBD1 modifications improve hCFTR- $\Delta F508$  processing. First, the variety of modifications, their disparate positions in NBD1, and their surface localizations suggest that enhanced maturation may not be caused by a markedly altered hmNBD1- $\Delta F508$  structure. Second, previous studies suggested that the region of NBD1 around F508 interacts with MSD2 and that by disrupting that association,  $\Delta F508$  impairs folding (15, 16, 19). Although it is possible that some NBD1 modifications repair an NBD1/MSD2 functional interaction, this mechanism does not explain the effect of the mouse RE or other widely dispersed NBD1 modifications. Moreover, as we discuss further below, interventions that do appear to modify NBD1/MSD2 interactions did not rescue CFTR- $\Delta F508$  biosynthesis. Third, although it is possible that modifying the solvent-exposed NBD1 surface changes contacts with other parts of CFTR, some of the regions modified are not predicted to touch other CFTR domains. Fourth, NBD1 modifications might change interactions with chaperones or associated proteins, and thereby facilitate CFTR- $\Delta F508$  progression through the biosynthetic pathway. This possibility could explain how the broad varieties of NBD1 modifications located far away from F508 enhance CFTR- $\Delta F508$  maturation.

**mMSD2 Sequences Prevent  $\Delta F508$ -Induced Gating Defects.** We found that substituting mouse for human MSD2 and ICL sequences altered gating. These results are consistent with previous studies suggesting that ICL4 couples NBD activity to gating of the pore (16, 32). However, our data go further by showing that mouse ICL sequences prevented  $\Delta F508$  from further altering gating. In addition, substituting mouse for human NBDs reverted the effect; an mNBD2 eliminated the protective effect of an ICL3 mutation, and an mNBD1 eliminated the protective effect of an ICL4 mutation. These results suggest that the region around F508 links to the ICLs of MSD2. They also suggest that loss of F508 alters the interaction of both NBDs with MSD2.

Previous reports have also suggested a connection between the NBDs and the ICLs. The crystal structure of Sav1866 (a half transporter containing one MSD and one NBD) revealed that the MSD ICLs contact the NBDs of the opposite subunit (14). Cysteine cross-linking experiments in CFTR also predicted that NBD2 contacts ICL1 and ICL2 and that NBD1 contacts ICL3 and ICL4. Additional studies predicted that the region surrounding F508 interacts with residues in ICL4 (15, 16, 23, 24). Our findings, plus these observations, suggest that the two NBDs form a functional unit that interfaces with ICL3 and ICL4 to transmit conformational NBD changes to the channel gate. And the  $\Delta F508$  mutation disrupts that process.

### mMSD2 Does Not Rescue CFTR- $\Delta F508$ Processing, and mNBD1 Does Not Prevent the Gating Defects.

A striking finding of our study was the difference between the effect of mouse sequences on CFTR- $\Delta F508$  gating and on processing. None of the substitutions modified both  $\Delta F508$ -induced misprocessing and  $\Delta F508$ -induced prolongation of the interburst interval. This distinction was exemplified by the I539T mutation. I539T improved processing; however, it not only failed to prevent the  $\Delta F508$  gating defect but actually further prolonged the interburst interval.

Other substitutions increased the  $P_o$  of CFTR- $\Delta F508$  by lengthening the burst duration rather than preventing  $\Delta F508$  from

increasing the interburst interval. For example, hmNBD1, which partially improved processing, increased the  $P_o$  with a prolonged burst duration instead of a shorter closed time. Other examples are the *G550E* and *R553K* mutations, which also partially rescued CFTR- $\Delta F508$  processing and increased the  $P_o$  by lengthening the burst duration. Although  $\Delta F508$  lengthened the interburst interval for both mutations, *G550E* reduced the magnitude of that increase (21, 26). In addition, a variant that combined *G550E* with *R553M* and *R553K* increased processing and current, although the effect on channel kinetics was not tested (33).

Our findings and consideration of earlier work suggest that the  $\Delta F508$  mutation affects two processes. First, it may impair NBD1 folding and/or stability, and that abnormality disrupts normal CFTR biosynthesis. This conclusion is consistent with studies on isolated NBD1 polypeptides (13, 20, 34). Second, it may impair interdomain interactions, and that abnormality disrupts normal CFTR gating. Thus, modifications of NBD1 or of MSD2 affect one or the other of these processes.

**Implications for Therapeutics.** There is a substantial effort to identify compounds that improve CFTR- $\Delta F508$  processing and/or function for therapeutic purposes. Our studies may have implications for such efforts. First, finding that I539T enhanced  $\Delta F508$ -CFTR processing but reduced its channel activity suggests that a drug screening strategy that only detects cell surface CFTR- $\Delta F508$  might miss adverse consequences for channel function. Second, the interface between NBD1 and ICL3 and ICL4 might be an important target for compounds that facilitate opening of  $\Delta F508$ -CFTR. Third, because many different NBD1 modifications improved CFTR- $\Delta F508$  maturation, it might be possible to target several different regions of NBD1 to enhance processing. In addition, finding that hmRE and I539T together improved CFTR- $\Delta F508$  processing more than either alone suggests that simultaneously targeting more than one NBD1 site might be beneficial. Fourth, the diversity of NBD1 modifications that improve CFTR- $\Delta F508$  biosynthesis suggested that modifications might alter interactions with chaperones and CFTR-associated proteins. Thus, targeting chaperones or a network of CFTR-associated proteins might be a reasonable therapeutic strategy. Fifth, because no one modification corrected both maturation and gating, perhaps more than a single agent will be required to correct all the CFTR- $\Delta F508$  defects.

## Materials and Methods

**Human–Mouse Chimera Constructs.** Plasmids encoding human WT and  $\Delta F508$  CFTR have been described (21, 35). Mouse *CFTR* cDNA was kind gift from Christopher Boyd (University of Edinburgh, Edinburgh, Scotland) and Brandon Wainwright (University of Queensland, Brisbane, QLD, Australia). We subcloned human, mouse, and all chimera *CFTR* cDNAs into pcDNA3.1 (Invitrogen). Most hmCFTR chimera constructs were generated by ligating vector and insert fragments that were each products of blunt-end PCR

(AccuPrime Pfx; Invitrogen). pcDNA3.1-hCFTR and pcDNA3.1-mCFTR were used as templates in all PCRs. All cDNAs were sequenced in their entirety to confirm proper sequence.

**Vectors and Expression.** For protein-processing studies, 293T cells were transfected with pcDNA3.1-human, mouse, and the human–mouse chimeric CFTR with or without the  $\Delta F508$  mutation using Lipofectamine 2000 (Invitrogen). For patch-clamp studies, HeLa cells were transfected with *CFTR* and variant cDNA plasmids and Lipofectamine 2000 24 h after cells were seeded. Patch-clamp studies were done 24 h after transfection. Cells were cultured at 37 °C. For some of the CFTR- $\Delta F508$  studies, cells were transferred to an incubator at 27 °C to correct the  $\Delta F508$ -induced processing defect, which allowed us to do patch-clamp studies 24–48 h later.

**Processing Studies.** 293T cells were lysed 48 h after transfection, solubilized in lysis buffer [50 mM Tris (pH 7.4), 50 mM NaCl, 1% Nonidet P-40 and proteinase inhibitors, 2  $\mu$ g/mL aprotinin, 7  $\mu$ g/mL benzamidine-HCl, 1  $\mu$ g/mL pepstatin A, and 2  $\mu$ g/mL leupeptin], and centrifuged at 70,000  $\times$  g for 20 min at 4 °C. CFTR in the supernatant was immunoprecipitated with M3A7 and MM13-4 antibodies (Upstate Biotechnology), and then phosphorylated with  $\gamma$ - $^{32}$ PATP and the catalytic subunit of cAMP-dependent protein kinase (PKA; Promega) as described (35). Immunoprecipitates were electrophoresed on 6% SDS/PAGE, dried, and exposed to a phosphor screen for visualization (Fuji7000).

**Patch-Clamp Studies.** We used excised, inside-out membrane patches. The pipette (extracellular) solution contained the following: 140 mM *N*-methyl-D-glucamine, 100 mM L-aspartic acid, 3 mM MgCl<sub>2</sub>, 5 mM CaCl<sub>2</sub>, and 10 mM Tricine (pH 7.3) with HCl (final Cl<sup>-</sup> concentration ~51 mM). The bath (intracellular) solution contained the following: 140 mM *N*-methyl-D-glucamine, 3 mM MgCl<sub>2</sub>, 1 mM cesium EGTA, and 10 mM Tricine (pH 7.3) with HCl (final Cl<sup>-</sup> concentration 140 mM). Following patch excision, channels were activated with the catalytic subunit of cAMP-dependent protein kinase (PKA; Calbiochem, EMD Chemicals, Inc.) and ATP. Unless otherwise specified, PKA was present in all cytosolic solutions that contained ATP. All nucleotides were from Sigma–Aldrich. ATP was added as the Mg<sup>2+</sup> salt. The holding voltage was –50 to –100 mV for single-channel experiments. Experiments were performed at room temperature (23–26 °C).

An Axopatch 200B amplifier (Axon Instruments, Inc.) was used for voltage clamping and current recording, and the pCLAMP software package (version 9.1; Axon Instruments, Inc.) was used for data acquisition and analysis. Data were digitized at 5 kHz. Current recordings were low-pass filtered at 500 Hz using an eight-pole Bessel filter (Model 900; Frequency Devices, Inc.) for analysis and at 100 Hz for display in figures (10 Hz for mCFTR display traces). Single-channel analysis was performed as previously described (36, 37) with a burst delimiter of 20 ms. Events  $\leq$  4 ms in duration were ignored. mCFTR subconductance opening was not taken into account in our studies (Fig. 3).

**ACKNOWLEDGMENTS.** We thank Philip Karp, Pamela Hughes, Ping Tan, Huiyu Gong, and Theresa Mayhew for excellent technical assistance. We thank the In Vitro Models and Cell Culture Core for assistance, supported, in part, by National Heart, Lung, and Blood Institute Grants HL091842 and HL51670; Cystic Fibrosis Foundation Grants R458-CR02 and ENGLH9850; and National Institute of Diabetes and Digestive and Kidney Disease Grant DK54759. This work was also supported by National Institutes of Health Grant HL61234 and Cystic Fibrosis Foundation Grant OSTEDG06G0. M.J.W. is a Howard Hughes Medical Institute Investigator.

- Riordan JR, et al. (1989) Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. *Science* 245:1066–1073.
- Welsh MJ, Tsui LC, Boat TF, Beaudet AL (1995) *Cystic fibrosis. The Metabolic and Molecular Basis of Inherited Disease*, eds Scriver CR, Beaudet AL, Sly WS, Valle D (McGraw–Hill, New York), 7th Ed, pp 3799–3876.
- Cheng SH, et al. (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. *Cell* 63:827–834.
- Lukacs GL, et al. (1994) Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. *EMBO J* 13:6076–6086.
- Ward CL, Kopito RR (1994) Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. *J Biol Chem* 269:25710–25718.
- Skach WR (2000) Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator. *Kidney Int* 57:825–831.
- Denning GM, et al. (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. *Nature* 358:761–764.
- Dalemans W, et al. (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. *Nature* 354:526–528.
- Lukacs GL, et al. (1993) The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. *J Biol Chem* 268:21592–21598.
- Swiatecka-Urban A, et al. (2005) The short apical membrane half-life of rescued  $\Delta F508$ -cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of  $\Delta F508$ -CFTR in polarized human airway epithelial cells. *J Biol Chem* 280:36762–36772.
- Lewis HA, et al. (2004) Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. *EMBO J* 23:282–293.
- Lewis HA, et al. (2005) Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. *J Biol Chem* 280:1346–1353.
- Thibodeau PH, Brautigam CA, Machiusi M, Thomas PJ (2005) Side chain and backbone contributions of Phe508 to CFTR folding. *Nat Struct Mol Biol* 12:10–16.
- Dawson RJ, Locher KP (2006) Structure of a bacterial multidrug ABC transporter. *Nature* 443:180–185.
- Loo TW, Bartlett MC, Clarke DM (2008) Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR). *J Biol Chem* 283:28190–28197.

16. Serohijos AW, et al. (2008) Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. *Proc Natl Acad Sci USA* 105:3256–3261.
17. Ostedgaard LS, et al. (2007) Processing and function of CFTR-DeltaF508 are species-dependent. *Proc Natl Acad Sci USA* 104:15370–15375.
18. DeCarvalho AC, Gansheroff LJ, Teem JL (2002) Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508. *J Biol Chem* 277:35896–35905.
19. He L, et al. (2010) Restoration of domain folding and interdomain assembly by second-site suppressors of the DeltaF508 mutation in CFTR. *FASEB J* 24:3103–3112.
20. Hoelen H, et al. (2010) The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain. *PLoS ONE* 5:e15458.
21. Teem JL, Carson MR, Welsh MJ (1996) Mutation of R555 in CFTR-ΔF508 enhances function and partially corrects defective processing. *Receptors Channels* 4:63–72.
22. Scott-Ward TS, et al. (2007) Chimeric constructs endow the human CFTR Cl<sup>-</sup> channel with the gating behavior of murine CFTR. *Proc Natl Acad Sci USA* 104:16365–16370.
23. He L, et al. (2008) Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis transmembrane conductance regulator (CFTR) mediate regulation of channel gating. *J Biol Chem* 283:26383–26390.
24. Mornon JP, Lehn P, Callebaut I (2008) Atomic model of human cystic fibrosis transmembrane conductance regulator: Membrane-spanning domains and coupling interfaces. *Cell Mol Life Sci* 65:2594–2612.
25. Teem JL, et al. (1993) Identification of revertants for the cystic fibrosis delta F508 mutation using STE6-CFTR chimeras in yeast. *Cell* 73:335–346.
26. Roxo-Rosa M, et al. (2006) Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. *Proc Natl Acad Sci USA* 103:17891–17896.
27. Pissarra LS, et al. (2008) Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. *Chem Biol* 15:62–69.
28. Hegedus T, et al. (2006) F508del CFTR with two altered RXR motifs escapes from ER quality control but its channel activity is thermally sensitive. *Biochim Biophys Acta* 1758:565–572.
29. Roy G, Chalfin EM, Saxena A, Wang X (2010) Interplay between ER exit code and domain conformation in CFTR misprocessing and rescue. *Mol Biol Cell* 21:597–609.
30. Kim Chiaw P, et al. (2009) Functional rescue of DeltaF508-CFTR by peptides designed to mimic sorting motifs. *Chem Biol* 16:520–530.
31. Aleksandrov AA, et al. (2010) Regulatory insertion removal restores maturation, stability and function of DeltaF508 CFTR. *J Mol Biol* 401:194–210.
32. Cotten JF, Ostedgaard LS, Carson MR, Welsh MJ (1996) Effect of cystic fibrosis-associated mutations in the fourth intracellular loop of cystic fibrosis transmembrane conductance regulator. *J Biol Chem* 271:21279–21284.
33. Thibodeau PH, et al. (2010) The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. *J Biol Chem* 285:35825–35835.
34. Wang C, et al. (2010) Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis. *Protein Sci* 19:1932–1947.
35. Ostedgaard LS, Zeiher B, Welsh MJ (1999) Processing of CFTR bearing the P574H mutation differs from wild-type and ΔF508-CFTR. *J Cell Sci* 112:2091–2098.
36. Carson MR, Travis SM, Welsh MJ (1995) The two nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator (CFTR) have distinct functions in controlling channel activity. *J Biol Chem* 270:1711–1717.
37. Cotten JF, Welsh MJ (1998) Covalent modification of the nucleotide binding domains of cystic fibrosis transmembrane conductance regulator. *J Biol Chem* 273:31873–31879.
38. Lansdell KA, Kidd JF, Delaney SJ, Wainwright BJ, Sheppard DN (1998) Regulation of murine cystic fibrosis transmembrane conductance regulator Cl<sup>-</sup> channels expressed in Chinese hamster ovary cells. *J Physiol* 512:751–764.